Volume 13, Number 4—April 2007
Transfusion-associated Hepatitis E, France
Highlight and copy the desired format.
|EID||Colson P, Coze C, Gallian P, Henry M, de Micco P, Tamalet C, et al. Transfusion-associated Hepatitis E, France. Emerg Infect Dis. 2007;13(4):648. https://dx.doi.org/10.3201/eid1304.061387|
|AMA||Colson P, Coze C, Gallian P, et al. Transfusion-associated Hepatitis E, France. Emerging Infectious Diseases. 2007;13(4):648. doi:10.3201/eid1304.061387.|
|APA||Colson, P., Coze, C., Gallian, P., Henry, M., de Micco, P., & Tamalet, C. (2007). Transfusion-associated Hepatitis E, France. Emerging Infectious Diseases, 13(4), 648. https://dx.doi.org/10.3201/eid1304.061387.|
To the Editor: Hepatitis E virus (HEV) is a leading cause of acute and fulminant hepatitis in developing countries (1). In industrialized countries, HEV seroprevalence rates of 0.4%–3% are common, and evidence is mounting that autochthonous transmission might account for a substantial proportion of infections (1–3). Whereas fecal-oral HEV transmission is preponderant in developing countries, other routes have been demonstrated in industrialized countries, among them consumption of pork or boar meat (1,4). Parenteral transmission was first suggested but not demonstrated (5,6). Because viruses cannot be fully inactivated in blood products, HEV recently emerged as a transfusion-transmitted pathogen, with 6 reported cases, including 3 in which comparative analysis of HEV sequences from blood donor and recipient was performed (7). We describe what is, to our knowledge, the first case in France and the first case worldwide involving a child as blood recipient.
A 7-year-old boy was examined in June 2006; he had erythematous-papulous skin and an increased level of alanine aminotransferase (ALT, 796 IU/L) of 1 week’s duration. From October 2005 to May 2006, he had received several courses of combined chemotherapy for a rhabdoid tumor in his kidney. Therapy included carboplatin, cyclophosphamide, etoposide, adriamycin, and vincristine, and, because of the tumor’s hematotoxicity, 22 transfusions of concentrated erythrocytes or platelets. Peak levels of ALT and bilirubin were reached 4 weeks after onset of hepatitis (2,001 IU/L and 49 μmol/L, respectively), and ALT levels returned to normal range (8–45 IU/L) 6 weeks later. During a follow-up examination, the boy’s prothrombin index remained >80%, and clinical signs mostly consisted of clinical jaundice. HEV diagnosis was established by detection of HEV antibodies in serum (EIAgen Kits, Adaltis Development Inc., Laval, Quebec, Canada) and HEV RNA with in-house assays. Other infectious or noninfectious causes of acute hepatitis were excluded. HEV immunoglobulin M (IgM) was weakly positive in June 2006 (optical density ratio = 1.6), then strongly positive the next month (ratio = 10.8); IgG remained negative. HEV RNA was detected from serum samples collected in June 2006 by an in-house real-time PCR that targeted the open reading frame 2 region of the HEV genome. Sequences of primers/probe are as follows: 5′-aattratttcgtcggcygg-3′; HevMrsRTRev: 5′acwgtcggctcgccattg-3′; HevMrsFam: 5′-FAM-actcycgccasgtygtctca-TAMRA-3′.
Serum samples taken from 12 U of packed erythroctyes that the child received, 1 U at a time, during the 3-months period before onset of hepatitis were tested for HEV RNA; 1 sample was positive. Concentrated erythrocytes (310 mL) from this positive blood donation were transfused to the child in May 2006, 4 weeks after collection and 6 weeks before acute hepatitis developed. HEV IgG and IgM antibodies were not detected in the blood donation, which indicates that the blood donation occurred during the prodromic phase of HEV disease. HEV nucleotide sequences from the blood donor and recipient were identical. Phylogenetic analysis showed that they clustered together and were closely related to genotype 3f, which is prevalent in Europe (Figure ).
The blood donor was a 24-year-old man. He did not travel outside metropolitan France for 8 months before donating blood. Anti-HEV IgG seroconversion was observed on a serum sample collected 24 weeks after blood donation, whereas anti-HEV IgM and serum HEV RNA tested negative. ALT levels were within normal values at the time of blood donation and 24 weeks later. No clinical signs were reported at any time. No other recipient received blood products from this donor.
Our data show that HEV was transmitted from 1 blood donor to the recipient child. On the basis of retrospective HEV RNA detection, 6 other transfusion-transmitted HEV infections, all involving adult blood recipients, have occurred in HEV-hyperendemic and industrialized countries (7). Transfusion-transmitted HEV strains belonged to different genotypes/subtypes that corresponded to those found in the same geographic areas (Figure).
In France, neither HEV antibodies nor HEV RNA are systematically tested in blood donors, and blood donations currently are not tested for ALT. In the absence of systematic HEV RNA testing, HEV diagnosis in blood donations may be hampered by HEV viremia before clinical onset and anti-HEV seroconversion, the possible short persistence or absence of HEV antibodies, and the high frequency of subclinical infections (1,2,5). On the basis of these data, improved knowledge of HEV epidemiology in the general population and in blood donors is needed in industrialized countries to guide HEV screening policy for blood products.
Another concern of transfusion-transmitted HEV infections is the potential severity of acute hepatitis E. Previously reported cases of contamination through transfusion and our case showed spontaneous recovery. However, although typically self-limited, hepatitis E is potentially life-threatening with mortality rates of 0.2%–4%, reaching 20% in pregnant women (1). Fatal outcome has also been described in children (10). In summary, HEV-contaminated blood donations are a challenge for diagnosis and virus safety of transfusion, including in industrialized countries.
We are indebted to Didier Raoult for his valuable comments and support and also to Dominique Legrand and Sophie Simon for their participation in the transfusion investigation.
- Worm HC, van der Poel WH, Brandstatter G. Hepatitis E: an overview. Microbes Infect. 2002;4:657–66.
- Peron JM, Mansuy JM, Poirson H, Bureau C, Dupuis E, Alric L, Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol. 2006;30:757–62.
- Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, Non-travel–associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis. 2005;192:1166–72.
- Li TC, Chijiwa K, Sera N, Ishibashi T, Etoh Y, Shinohara Y, Hepatitis E virus transmission from wild boar meat. Emerg Infect Dis. 2005;11:1958–60.
- Arankalle VA, Chobe LP. Hepatitis E virus: can it be transmitted parenterally? J Viral Hepat. 1999;6:161–4.
- Psichogiou MA, Tassopoulos NC, Papatheodoridis GV, Tzala E, Klarmann R, Witteler H, Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitis. J Hepatol. 1995;23:668–73.
- Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Transfusion-transmitted hepatitis E in a ‘nonhyperendemic’ country. Transfus Med. 2006;16:79–83.
- Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5–36.
- Mitsui T, Tsukamoto Y, Yamazaki C, Masuko K, Tsuda F, Takahashi M, Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. J Med Virol. 2004;74:563–72.
- Arora NK, Nanda SK, Gulati S, Ansari IH, Chawla MK, Gupta SD, Acute viral hepatitis types E, A, and B singly and in combination in acute liver failure in children in north India. J Med Virol. 1996;48:215–21.
- Figure. Outline of phylogenetic tree (complete figure available online, http://www.cdc.gov/EID/13/4/zzz-T.htm) constructed by the neighbor-joining method on the basis of partial nucleotide sequences of the open reading frame (ORF) 2 region of...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Philippe Colson, Laboratoire de Virologie, Fédération Hospitalière de Bactériologie-Virologie Clinique et d’Hygiène, CHRU Timone, 264 rue Saint-Pierre 13385, Marseille cedex 05, France; email address:
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 28, 2010
- Page last updated: June 28, 2010
- Page last reviewed: June 28, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)